NCT07068555View on ClinicalTrials.gov

Prostate Cancer Vaccines

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

June 15, 2025

Primary Completion Date

June 15, 2028

Study Completion Date

December 15, 2028

Conditions
Prostate Cancer Indications
Interventions
BIOLOGICAL

Immunomodulatory DC vaccines to target prostate cancer

1 to 2 injections, with an interval of one month, of 1\~2x10\^7 DC vaccine administered subcutaneously

Trial Locations (1)

518000

RECRUITING

Shenzhen Geno-immune Medical Institute, Shenzhen

All Listed Sponsors
lead

Shenzhen Geno-Immune Medical Institute

OTHER

NCT07068555 - Prostate Cancer Vaccines | Biotech Hunter | Biotech Hunter